gefitinib has been researched along with tyrosine in 27 studies
Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (tyrosine) | Trials (tyrosine) | Recent Studies (post-2010) (tyrosine) |
---|---|---|---|---|---|
5,231 | 566 | 2,919 | 44,273 | 846 | 8,225 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 17 (62.96) | 29.6817 |
2010's | 8 (29.63) | 24.3611 |
2020's | 2 (7.41) | 2.80 |
Authors | Studies |
---|---|
Coll, JL; Dubrez, L; Favrot, MC; Hurbin, A | 1 |
Archer, GE; Bigner, DD; Chewning, TA; Friedman, AH; Friedman, HS; Heimberger, AB; Learn, CA; McLendon, RE; Pracyk, JB; Sampson, JH; Tuck, FL | 1 |
Angelucci, A; Bologna, M; Festuccia, C; Gravina, GL; Marronaro, A; Vicentini, C | 1 |
Bell, DW; Haber, DA; Settleman, J; Sordella, R | 1 |
Kikuchi, K; Nakanishi, K; Ohsaki, Y; Tanno, S; Toyoshima, E | 1 |
Koh, Y; Koizumi, F; Nishio, K; Saijo, N; Taguchi, F; Tamura, T | 1 |
Baldi, E; Bonaccorsi, L; Carloni, V; Forti, G; Marchiani, S; Muratori, M | 1 |
Kishida, O; Kiyohara, T; Miyazaki, T; Miyazaki, Y; Murayama, Y; Ogasa, M; Shimomura, I; Shinomura, Y; Tsutsui, S; Watabe, K; Yamamoto, T | 1 |
Chen, YR; Chen, YT; Fu, YN; Hu, SF; Huang, SF; Lin, CH; Tsai, SF; Yang, ST | 1 |
Cody, DD; Dackor, J; Fujimoto, N; Hanna, AE; Herbst, R; Iwanaga, K; Kalyankrishna, S; Kurie, JM; Massarelli, E; Minna, JD; Peyton, M; Price, RE; Sato, M; Shay, JW; Tang, X; Threadgill, DW; Wislez, M; Wistuba, II; Zhang, J | 1 |
Ariyama, H; Baba, E; Harada, M; Kusaba, H; Nakano, S; Qin, B; Tanaka, R | 1 |
Furukawa, M; Goya, S; Greene, MI; Kawase, I; Kijima, T; Kumagai, T; Matsuoka, H; Nagatomo, I; Osaki, T; Tachibana, I; Takahashi, R; Takeda, Y; Yamadori, T; Yoneda, T; Yoshida, M; Yoshimura, M | 1 |
Chen, YR; Cheng, HH; Fu, YN; Huang, SF; Tsai, SF; Yang, CH; Yeh, CL | 1 |
Bongarzone, I; Cassinelli, G; Cremona, M; Cuccuru, G; Gorla, L; Lanzi, C; Miccichè, F; Mondellini, P; Pierotti, MA | 1 |
Cheng, LC; Chua, DT; Chung, LP; Leung, EL; Sihoe, AD; Tam, IY; Tin, VP; Wong, MP | 1 |
Downing, JR | 1 |
Berchuck, JE; Carr, SA; Carroll, M; Clauser, K; Davis, TN; DeAngelo, DJ; Galinsky, I; Golub, TR; Hahn, CK; Hahn, WC; Kakoza, RM; Kung, AL; Root, DE; Ross, KN; Ross, L; Schinzel, AC; Silver, SJ; Stegmaier, K; Stone, RM | 1 |
Becker, A; Chiappori, A; Haura, EB; Sommers, E; Song, L | 1 |
Abbott, DW; Asara, JM; Tigno-Aranjuez, JT | 1 |
Azzoli, CG; Bains, M; Chaft, JE; Downey, R; Flores, R; Heelan, RT; Kris, MG; Krug, LM; Ladanyi, M; Miller, VA; Pao, W; Park, B; Rizvi, NA; Rusch, V; Shen, R; Singh, B; Zakowski, M | 1 |
Cavenee, WK; Furnari, F; Gonias, SL; Hu, J; Jo, M; VandenBerg, SR | 1 |
Ding, L; He, W; Hu, Y; Shen, X; Tan, F; Wang, D; Wang, Y; Xie, G; Zhang, X | 1 |
Anderson, KS; Apetri, M; Kim, Y; Li, Z; Luo, B; Settleman, JE | 1 |
Assiddiq, BF; Chan, SP; Chong, PK; Lim, YP; Tan, KY; Toy, W | 1 |
Ang, KK; Chang, SS; Chang, WC; Chen, CH; Cheng, CC; Hsu, MC; Hung, MC; Lan, L; Lavin, M; Lee, HJ; Liao, HW; Lin, SY; Nakajima, S; Peng, G; Wang, YN; Wei, L | 1 |
Gou, Q; Hou, Y; Jiang, Y; Shi, J; Xu, H; Xu, Y; Zhang, R; Zhang, W | 1 |
Cao, L; Chen, G; Cheng, Y; Cui, J; Feng, J; Gu, C; Hao, Y; Jiang, Y; Li, Y; Liu, C; Liu, F; Liu, J; Liu, Y; Shi, Y; Wang, X; Wu, L; Yang, N; Zang, A; Zhang, S; Zhang, X; Zhao, H; Zhu, S | 1 |
3 trial(s) available for gefitinib and tyrosine
Article | Year |
---|---|
Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Catalytic Domain; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome; Tyrosine | 2011 |
Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Crown Ethers; Disease-Free Survival; Double-Blind Method; Drug Evaluation, Preclinical; ErbB Receptors; Female; Gefitinib; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Tyrosine | 2012 |
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Tyrosine | 2022 |
24 other study(ies) available for gefitinib and tyrosine
Article | Year |
---|---|
Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines.
Topics: Amphiregulin; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Culture Media, Conditioned; Dose-Response Relationship, Drug; EGF Family of Proteins; Gefitinib; Glycoproteins; HeLa Cells; Humans; Intercellular Signaling Peptides and Proteins; Jurkat Cells; Kinetics; Lung Neoplasms; Phosphorylation; Precipitin Tests; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, IGF Type 1; Time Factors; Tumor Cells, Cultured; Tyrosine; Tyrphostins | 2002 |
Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).
Topics: 3T3 Cells; Administration, Oral; Animals; Antineoplastic Agents; Blotting, Western; Brain Neoplasms; DNA Mutational Analysis; Enzyme Inhibitors; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Time Factors; Tumor Cells, Cultured; Tyrosine | 2002 |
Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Division; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; In Vitro Techniques; Male; Phosphorylation; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Tumor Cells, Cultured; Tyrosine | 2003 |
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Catalytic Domain; Cell Line; Cell Line, Tumor; Cell Survival; DNA-Binding Proteins; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mice; Milk Proteins; Mitogen-Activated Protein Kinases; Mutation; Mutation, Missense; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Small Interfering; Sequence Deletion; Signal Transduction; STAT5 Transcription Factor; Trans-Activators; Transfection; Tyrosine | 2004 |
Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib ("Iressa", ZD1839).
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Small Cell; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Immunoprecipitation; Lung Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Tumor Cells, Cultured; Tyrosine | 2004 |
Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gefitinib; Lung Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured; Tyrosine; Xenograft Model Antitumor Assays | 2004 |
Signaling mechanisms that mediate invasion in prostate cancer cells.
Topics: Androgens; Cell Line, Tumor; Cell Proliferation; Collagen; Drug Combinations; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunoprecipitation; Laminin; Male; Neoplasm Invasiveness; Phenotype; Phosphatidylinositol 3-Kinases; Phosphorylation; Prostatic Neoplasms; Proteoglycans; Quinazolines; Receptors, Androgen; Signal Transduction; Transfection; Tyrosine | 2004 |
Gefitinib (Iressa, ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells.
Topics: Amphiregulin; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Screening Assays, Antitumor; EGF Family of Proteins; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glycoproteins; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Interleukin-8; Irinotecan; Phosphorylation; Quinazolines; Reactive Oxygen Species; Signal Transduction; Stomach Neoplasms; Transforming Growth Factor alpha; Tyrosine | 2005 |
Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chlorocebus aethiops; COS Cells; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Immunoprecipitation; Lung Neoplasms; Mutation; Phosphorylation; Quinazolines; Tumor Cells, Cultured; Tyrosine; Ubiquitin | 2006 |
High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, ras; Humans; Ligands; Lung Neoplasms; Mice; Mice, Knockout; Mutation; Neoplasms, Glandular and Epithelial; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Tumor Cells, Cultured; Tyrosine | 2005 |
Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Benzoquinones; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Gallbladder; Gefitinib; Humans; Inhibitory Concentration 50; Lactams, Macrocyclic; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins pp60(c-src); Quinazolines; Rifabutin; Signal Transduction; Tyrosine | 2006 |
Gefitinib-sensitive EGFR lacking residues 746-750 exhibits hypophosphorylation at tyrosine residue 1045, hypoubiquitination, and impaired endocytosis.
Topics: Animals; Binding Sites; Chlorocebus aethiops; COS Cells; Drug Resistance, Neoplasm; Endocytosis; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Ligands; Mice; Mutation; Phosphorylation; Phosphotyrosine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Quinazolines; Sequence Deletion; Tyrosine; Ubiquitin | 2007 |
EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy.
Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Gefitinib; Humans; Immunoprecipitation; Lung Neoplasms; Phosphorylation; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins pp60(c-src); Pyrimidines; Quinazolines; Sequence Deletion; Tyrosine | 2008 |
Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements.
Topics: Animals; Antineoplastic Agents; Carcinoma, Medullary; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Germ-Line Mutation; Humans; Mice; Mice, Nude; Multiple Endocrine Neoplasia Type 2a; Multiple Endocrine Neoplasia Type 2b; Oncogene Proteins; Phosphorylation; Proteomics; Proto-Oncogene Proteins c-ret; Quinazolines; Signal Transduction; Thyroid Neoplasms; Tyrosine | 2009 |
Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Phosphorylation; Quinazolines; Tyrosine | 2009 |
Can treating the SYK cell cure leukemia?
Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Differentiation; Cell Proliferation; Dose-Response Relationship, Drug; Gefitinib; Gene Expression Regulation, Leukemic; Genomics; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Morpholines; Oxazines; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyridines; Pyrimidines; Quinazolines; Syk Kinase; Time Factors; Tyrosine | 2009 |
Proteomic and genetic approaches identify Syk as an AML target.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Differentiation; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Genomics; HL-60 Cells; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Morpholines; Oxazines; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyridines; Pyrimidines; Quinazolines; RNA Interference; Syk Kinase; Tandem Mass Spectrometry; Time Factors; Tumor Cells, Cultured; Tyrosine; U937 Cells; Xenograft Model Antitumor Assays | 2009 |
A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Phosphorylation; Pilot Projects; Prognosis; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Survival Rate; Tissue Distribution; Tyrosine | 2010 |
Inhibition of RIP2's tyrosine kinase activity limits NOD2-driven cytokine responses.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Animals; Cells, Cultured; Cytokines; Enzyme Activation; Erlotinib Hydrochloride; Gefitinib; Gene Knockout Techniques; HEK293 Cells; HT29 Cells; Humans; Mice; Nod2 Signaling Adaptor Protein; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor-Interacting Protein Serine-Threonine Kinase 2; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination | 2010 |
Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.
Topics: Animals; Antibiotics, Antineoplastic; Brain; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Doxorubicin; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioblastoma; Humans; Immunoblotting; Mice; Mice, Nude; Mice, SCID; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor Cross-Talk; Receptors, Urokinase Plasminogen Activator; RNA Interference; STAT5 Transcription Factor; Transplantation, Heterologous; Tyrosine | 2011 |
Temporal resolution of autophosphorylation for normal and oncogenic forms of EGFR and differential effects of gefitinib.
Topics: Apoptosis; Cell Differentiation; Cell Proliferation; Down-Regulation; Drug Delivery Systems; Drug Design; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Phosphorylation; Quinazolines; Spectrometry, Mass, Electrospray Ionization; Time Factors; Tyrosine | 2012 |
EGFR S1166 phosphorylation induced by a combination of EGF and gefitinib has a potentially negative impact on lung cancer cell growth.
Topics: Amino Acid Motifs; Amino Acid Sequence; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Molecular Sequence Data; Peptide Fragments; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; Serine; Tandem Mass Spectrometry; Tyrosine | 2012 |
Tyrosine 370 phosphorylation of ATM positively regulates DNA damage response.
Topics: Amino Acid Sequence; Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; Checkpoint Kinase 2; DNA Breaks, Double-Stranded; DNA Repair; ErbB Receptors; Gefitinib; HeLa Cells; Humans; Phosphorylation; Quinazolines; Radiation, Ionizing; RNA Interference; RNA, Small Interfering; Signal Transduction; Tyrosine | 2015 |
PPARδ is a regulator of autophagy by its phosphorylation.
Topics: Autophagy; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; HCT116 Cells; Humans; Microtubule-Associated Proteins; Mutation; Phosphorylation; PPAR delta; Protein Binding; Protein Kinase Inhibitors; Tyrosine | 2020 |